Epizyme

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.   Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Epizyme A Buy For Tazverik And Epigenetic Platform

Continental Resources

Twenty-First Century Fox

Groupon

Axis Capital

Cardtronics

Con Ed

Royalty Pharma

Vistra Energy

WesBanco

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Notable Insider Buys: Continental Resources, Fox, Groupon And More

The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.

Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?

Shares of Epizyme Inc. EPZM, +4.81% were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory follicular lymphoma.

Epizyme's shares fall after receiving new FDA approval for cancer drug

The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.

Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma

G1 Therapeutics

If you have cash to spare, these cancer stocks are set to soar.

2 Top Cancer Treatment Stocks to Buy in June

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?

Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced

Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions

Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.

Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss

Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2020 Results - Earnings Call Transcript

Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates

  Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.

Epizyme: Q1 Earnings Insights

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Epizyme (EPZM) Q1 Earnings Expected to Decline

Aimmune Therapeutics

Esperion Therapeutics

Horizon Pharma

These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.

Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?

Investors were looking forward to the drug company's transition to commercial operations, but the coronavirus pandemic could delay the maturation process.

Here's Why Epizyme Lost 27.6% in March

Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound?

Exelixis

Immunomedics

Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.

3 Cancer Treatment Stocks to Buy Right Now

Bristol-Myers

GlaxoSmithKline

On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts It's

Smart Money Is Clamoring to Own This Cancer-Fighting Biotech

Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.

Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat

Epizyme Inc. (EPZM) CEO Rob Bazemore on Q4 2019 Results - Earnings Call Transcript

The pharma company released full-year 2019 operating results.

Here's Why Epizyme Is Tumbling Today

We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.

Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?

Epizyme's NDA Accepted, And Other News: The Good, Bad And Ugly Of Biopharma

News for Epizyme Stock (EPZM)